Quell Therapeutics has raised a whopping US$156m from a prestigious investor group in an oversubscribed Series B financing. With the funds, the British biotech wants to hasten its CAR-Treg cell therapy candidate on its way to the clinic.

Vaccibody rebrands as Nykode Therapeutics and teams up with Regeneron in a vaccine deal potentially worth US$925m.

Dr Nicolas Gaudenzio has been started at the beginning of November as Chief Scientific Officer of Genoskin.

The European Commission has inked the pre-purchase agreement over Valneva’s inactivated whole virus pandemic vaccine VLA2001 announed in mid-October.

Swiss Vifor Pharma is shelling out more than €375m for Mallorca-based Sanifit, a clinical-stage cardio-renal biopharmaceutical company with a single compound in development.

Novo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.

On 7th July 2021, the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte – BfArM) launched the first sale of cannabis exclusively for medical purposes from cultivation in Germany. Pharmacies are now able to purchase medical cannabis flowers of pharmaceutical drug quality for the supply of patients from the BfArM via the official portal of the German Cannabis Agency (www.cannabisagentur.de).

Lotta Ferm, interim CFO of Immunicum AB, was now named as Chief Financial Officer.

Pfizer Inc announced it will  allow generic makers in 95 low income nations to produce and distribute its COVID-19 pill Paxlovid at cost price.

London-based Synthace, which develops software to automate biology experimentation, has raised US$35m in a Series C from notable investors.